Novartis Dismisses Some Exelon Patent Claims

Law360, New York (April 23, 2007, 12:00 AM EDT) -- A federal judge on Thursday approved Novartis Pharmaceuticals Corp.’s requests to dismiss claims for infringement of one patent involved in a multidistrict dispute over Exelon, the Swiss drug maker’s Alzheimer’s treatment.

U.S. Magistrate Judge James C. Francis IV of the U.S. District Court for the Southern District of New York approved Novartis’ motion to dismiss claims it had brought against Watson Pharmaceuticals Inc. and Sun Pharmaceutical Industries Ltd. for infringement of U.S. Patent Number 5,602,176, but only after some additional conditions are added to Novartis’ agreements...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.